Department of Pharmacology and Clinical Pharmacology, Istanbul University, Istanbul, Turkey.
Minerva Med. 2013 Jun;104(3):287-93.
Fetuin-A is an endogenous inhibitor of the insulin-stimulated insulin receptor tyrosine kinase recently shown that high levels of circulating fetuin-A are associated with insulin resistance in humans suggesting that fetuin-A may represent a novel mechanism involved in the pathophysiology of type 2 diabetes (T2DM). Dietary omega-3 polyunsaturated fatty acids (n-3 PUFAs) are known to reduce triglyceride levels, but their impact on glycemic control are not well known. The aim of this study to determine the effects of omega-3 PUFA supplementation on fetuin-A and glycemic control in patients with type 2 diabetes mellitus. 40 T2DM patients (17 males/23 females; aged 39-65 years) were included in the study. Serum fetuin-A levels and metabolic and biochemical profiles were measured before (baseline) and two months after n-3 PUFA supplementations (1.2 g/day). Serum fetuin-A levels were measured by enzyme-linked immunosorbent assay. Our results indicated that serum fetuin-A, fasting glucose, HbA1c and triglyceride levels were significantly decreased after supplementation (P<0.02, P<0.001, P<0.02 and P<0.01, respectively). At baseline, serum fetuin-A levels were correlated with HbA1c (r:-0.391, P<0.04). A significant positive correlation between fetuin-A and both triglycerides (r: 0.343, P<0.05) and total cholesterol (r: 0.330, P<0.05) and negative correlation between fetuin-A and fasting glucose (r: -0.405, P<0.01) were found after the supplementations. When performed multiply regression analysis, we found that serum fetuin-a levels were related with triglyceride levels (r: 0.351, P<0.01) at baseline and HbA1c levels (r: 0.344, P<0.04) after the supplementation. Based on the results, it thought that omega-3 PUFA intake decreases serum fetuin-A levels and serum fetuin-A is associated with plasma lipids and glycemic controls in type 2 diabetic patients. Further studies are required to resolve the question.
胎球蛋白 A 是一种内源性胰岛素刺激的胰岛素受体酪氨酸激酶抑制剂，最近的研究表明，循环胎球蛋白 A 水平升高与人类的胰岛素抵抗有关，这表明胎球蛋白 A 可能代表 2 型糖尿病 (T2DM) 病理生理学中的一种新机制。已知膳食 ω-3 多不饱和脂肪酸 (n-3 PUFA) 可降低甘油三酯水平，但它们对血糖控制的影响尚不清楚。本研究旨在确定 ω-3 PUFA 补充剂对 2 型糖尿病患者胎球蛋白 A 和血糖控制的影响。40 名 2 型糖尿病患者（17 名男性/23 名女性；年龄 39-65 岁）纳入本研究。在补充前（基线）和 n-3 PUFA 补充两个月后（每天 1.2 克）测量血清胎球蛋白 A 水平和代谢及生化谱。通过酶联免疫吸附试验测量血清胎球蛋白 A 水平。我们的结果表明，补充后血清胎球蛋白 A、空腹血糖、HbA1c 和甘油三酯水平显著降低（P<0.02、P<0.001、P<0.02 和 P<0.01，分别）。在基线时，血清胎球蛋白 A 水平与 HbA1c 相关（r：-0.391，P<0.04）。补充后，胎球蛋白 A 与甘油三酯（r：0.343，P<0.05）和总胆固醇（r：0.330，P<0.05）呈显著正相关，与空腹血糖呈负相关（r：-0.405，P<0.01）。进行多元回归分析后，我们发现血清胎球蛋白 A 水平与基线时的甘油三酯水平（r：0.351，P<0.01）和补充后的 HbA1c 水平（r：0.344，P<0.04）相关。基于这些结果，我们认为 ω-3 PUFA 的摄入可降低血清胎球蛋白 A 水平，而血清胎球蛋白 A 与 2 型糖尿病患者的血脂和血糖控制有关。需要进一步的研究来解决这个问题。
